456070.KQ
Encell Co. Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 5,400.00
−3.74%Year over year
Reported trailing growth
- Revenue
- -28.6%
- EBITDA
- -53.4%
- EBIT
- +22.4%
- EPS
- +4.1%
- Free cash flow
- -6.3%
- Operating cash flow
- +8.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -10.6%
- EBITDA
- -39.7%
- EBIT
- -21.7%
- Net income
- -5.9%
- EPS
- +14.3%
- Free cash flow
- -24.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026